Medtronic plc (NYSE:MDT) drew a broad round of price-target increases after its fiscal 2027 first-quarter results, but Wall Street remains divided over whether accelerating growth can support a meaningful re-rating of the stock.
The acceleration follows an earlier debate over whether Medtronic (MDT) is finally becoming a turnaround story.
Bull Case: Growth Is Broadening
Mizuho raised its target to $115 from $100 and maintained Outperform after Medtronic plc (NYSE:MDT) reported 13.7% organic revenue growth. Analyst Anthony Petrone highlighted roughly 7% organic growth across cardiovascular products, with Cardiac Ablation Solutions and new products driving upside.
BofA also raised its target to $110 from $95 with Buy, saying growth drivers are emerging across nearly every business outside CAS. Wells Fargo increased its target to $104 from $102 with Overweight, pointing to the Q1 beat, CAS strength, and potential upside to fiscal 2027 guidance.
The results gave those views additional support. The quarter included an extra fiscal week, which Medtronic estimated contributed about $570 million to revenue. Management subsequently raised its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from 6.75%-7.25%.
CAS remained the standout, with revenue up 88%, while CRM, Pelvic Health and diabetes each grew 15%. Management expects CAS to grow more than 2.5 times its market in fiscal 2027.
Bear Case: Growth May Not Yet Merit a Re-Rating
The more cautious analysts also raised their targets, but their ratings show the remaining debate. Deutsche Bank lifted its target to $92 from $78 with Hold, Truist moved to $99 from $86 with Hold, and Stifel raised its target to $95 from $80 with Hold.
Baird raised its target to $100 from $91 with Neutral, acknowledging the impressive growth acceleration but remaining less convinced that Medtronic plc (NYSE:MDT) deserves a higher valuation multiple. BTIG, meanwhile, raised its target to $100 from $91 with Buy but flagged questions around the durability of Hugo following Medtronic’s $700 million investment in Cornerstone Robotics.
Medtronic plc (NYSE:MDT) is also reinvesting part of its revenue upside into commercial acceleration and M&A. The Cornerstone investment creates foregone interest, while management has increased acquisitions and investments significantly over the past year.
Hedge Funds Add as Short Interest Falls
The institutional picture moved favorably in Q2. First Eagle Investment Management increased its stake 38% to 13.78 million shares, Arrowstreet Capital raised its position 177% to 12.89 million, Citadel added 447% to 5.37 million, D.E. Shaw increased 392% to 4.40 million, and AQR raised its position 103% to 3.30 million.
Short interest fell to 12.13 million shares as of August 31 from 18.12 million a month earlier, a decline of about 33%. Short interest represented 0.95% of shares outstanding, with a 1.74-day short ratio.
Valuation Is the Next Test
Medtronic plc (NYSE:MDT) traded at a forward P/E of 15.1 as of September 22. The question for Wall Street is whether broader growth can persist beyond CAS and support that valuation. The December 10-11 Investor Day could provide the next major update on the company’s longer-term growth trajectory.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Hedge Fund Resource Center